Drug Profile
MLN 2201
Alternative Names: Anti-b2 monoclonal antibody; Anti-CD18 monoclonal antibody LDP-01; LDP 01; MLN 01Latest Information Update: 20 Oct 2003
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Integrin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Reperfusion injury
Most Recent Events
- 10 Oct 2003 Discontinued - Phase-I for Reperfusion injury in USA (unspecified route)
- 10 Oct 2003 Discontinued - Preclinical for Reperfusion injury in United Kingdom (unspecified route)
- 25 Jun 2003 Phase-I clinical trials in Reperfusion injury in USA (unspecified route)